


Curriculum Vitae

Name	Hong Jae Chon, MD, PhD	
Current Position & Affiliation	Director of Cancer Center, CHA Bundang Medical Center	
Country	Korea	
Educational Background		

1998.3.-2005.2. **MD, Yonsei University College of Medicine, Seoul, Korea.**
 2008.3.-2018.8. **PhD, Yonsei Graduate School, Seoul, College of Medicine, Korea,**
 Supervised by Professor Joong Bae Ahn
**Doctoral thesis: “Combination immunotherapy of oncolytic virus
 and immune checkpoint inhibitor in renal cell carcinoma”**

Professional Experience	
2005.3.-2006.2.	Internship, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2006.3.-2010.2.	Residency in Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2013.5.-2014.2	Clinical Fellow, Division of Medical Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2014.3-2015.8	Clinical Research Professor, Division of Medical Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2015.9.-	Assistant Professor, Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea

- 2016.1.-** **Co-Director, Laboratory of Tumor Vasculature and Microenvironment, CHA University, Pangyo, Seongnam, Korea (<https://sites.google.com/view/ltio>)**
- 2019.3.-** **Associate Professor, Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea**
- 2019.8.- 2020.2** **Deputy Chief of Research, CHA Bundang Medical Center, Seongnam, Korea**
- 2020.3.-** **Director of Cancer Center, CHA Bundang Medical Center, Seongnam, Korea**

Main Scientific Publications

1. Kim CG, Kim C, Yoon SE, Kim KH, Choi SJ, Kang B, Kim HR, Park SH, Shin EC, Kim YY, Kim DJ, Chung HC, **Chon HJ***, Choi HJ, Lim HY. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. *Journal of Hepatology* 2020 (IF 20.582) (***Co-corresponding author**)
2. Lee YS, Lee WS, Kim CW, Lee SJ, Yang H, Kong SJ, Ning J, Yang KM, Kang B, Kim WR, **Chon HJ***, Kim C. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with PD-1 blockade to suppress peritoneal carcinomatosis in colon cancer. *J Immunother Cancer* 2020 (IF 10.252) (***Co-corresponding author**)
3. Cheon JK*, **Chon HJ***, Bang Y, Park NK, Shin JW, Kim KM, Lee Han Chu, Lee J, Yoo C, Ryoo BY. Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. *Liver Cancer* 2020 (IF 9.720) (***Co-first author**)
4. Yoo CH, Gyeon SG, Bang YH, Cheon JK, Kim JW, Kim JH, **Chon HJ**, Kang BD, Kang MJ, Kim IH, Hwang JE, Kang JH, Lee MA, Hong JY, Lim HY, Ryoo BY. Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. *Liver International* 2020
5. Kim HD, Bang YH, Lee MA, Kim JW, Kim JH, **Chon HJ**, Kang BD, Kang MJ, Kim LH, Cheon JK, Hwang JE, Kang JH, Byeon SG, Hong JY, Roo BY, Lim HY, Yoo CH. Regorafenib in patients with advanced Child-Pugh B hepatocellular

carcinoma: A multicentre retrospective study. *Liver International* 2020

6. Chae HJ, Jeong HH, Cheon JK, **Chon HJ**, Ryu HW, Kim IH, Kang MJ, Jeong JH, Ryoo BY, Kim KP, Yoo CH. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. *Therapeutic Advances in Medical Oncology* 2020
7. **Chon HJ**, and C Kim. REACH-2: first biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma. *Chinese Clinical Oncology* 2020 (**first author**)
8. Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, Kim S, Kim G, **Chon HJ***, and C Kim. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. *The Journal of Clinical Investigation* 2019 (IF 12.282) (***Co-corresponding author**)
9. **Chon HJ***, Kim HJ*, Noh JH, Yang HN, Lee WS, Kong SJ, Lee SJ, Lee YS, Kim WR, Kim JH, Kim, GI, and Kim C. STING signaling is a potential immunotherapeutic target in colorectal cancer. *Journal of Cancer* 2019 (IF 3.182) (***Co-first author**)
10. Yoo CH, Im HS, Kim KP, Oh DY, Lee KH, **Chon HJ**, Kim JH, Kim IH, Lee GJ, Oh SY, Choi YN, Cho HJ, Kim ST, Park JH, and Ryoo BY. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. *Therapeutic Advances in Medical Oncology* 2019 (IF: 5.67)
11. Kim C*, **Chon HJ***, Kim JH, Jung M, Nam JM, Kim HS, Kang B, Chung HC, Rha SY. Randomized phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. *European Journal of Cancer* 2019 (IF 7.191) (***Co-first author**)
12. **Chon HJ***, Lee WS*, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, Kim JH, Kim C. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade. *Clinical Cancer Research* 2019 (IF 10.199)
13. **Chon HJ***, Kim C*, Cho A, Kim YM, Jang SJ, Kim BO, Park CH, Hyung WJ, Ahn JB, Noh SH, Yun M, Rha SY. The Clinical Implications of FDG-PET/CT Differ According to Histology in Advanced Gastric Cancer. *Gastric Cancer* 2019

14. Kim C, Kim WR, Kim KY, **Chon HJ**, Beom SH, Kim H, Jung M, Shin SJ, Kim N, Ahn JB. Predictive Nomogram for Recurrence of Stage I Colorectal Cancer Following Curative Resection. *Clinical Colorectal Cancer 2018* (IF 4.507);17(3):e513-e518.
15. Kim HS, **Chon HJ**, Kim HK, Shin SJ, Wacheck Volker, Gruver AM, Kim JS, Rha SY, Chung HC. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis. *Journal of SURGICAL ONCOLOGY 2018* (IF 2.886)
16. Kim C*, Lee C*, **Chon HJ***, Kim JH, Park HS, Heo SJ, Kim HJ, Kim TS, Kwon WS, Chung HC, Rha SY. PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. *Oncotarget 2017* (IF 5.168), 8(69):113494-501 (***Co-first author**)
17. Park HS, Park JS, Chun YJ, Roh YH, Moon J, **Chon HJ**, Choi HJ, Park JS, Lee DK, Lee SJ, Yoon, DS, Jeung HC. Prognostic factors and scoring model for survival in metastatic biliary tract cancer. *Cancer Res Treat 2017* (IF 3.230)
18. **Chon HJ***, Hyung WJ*, Kim, C, Park SH, Kim JH, Park CH, Ahn JB, Kim HK, Chung HC, Rha SY, Noh SH, Jeung HC. Different implication of gastric signet ring cell carcinoma. *Annals of Surgery 2017* (IF 9.203)
19. Kim C, Yoo KH, Kim MH, **Chon HJ**, Lee SI, Koh S, Lee HY, Lee HR, Kim KS, Choi YD, Rha SY, Lee SJ, Kim HS. Different Subtypes of Epithelioid Sarcoma and Their Clinical Implication: Long-term Multi-Institutional Experience with a Rare Sarcoma. *APMIS 2017* (IF 1.933), 125:223-229
20. Kim C, Kim EK, Jung H, **Chon HJ**, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim SH, Kim HS. Prognostic Implications of PD-L1 Expression in Patients with Soft Tissue Sarcoma. *BMC Cancer 2016* (IF 3.265), 16:434
21. Lim SM, Kim YN, Park KH, Kang BD, **Chon HJ**, Kim C, Kim JH, Rha SY. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. *BMC Cancer 2016* (IF 3.265), 16:385
22. Kim C, Yang H, Park I, **Chon HJ**, Kim JH, Kwon WS, Lee WS, Kim TS, Rha SY. Rho GTPase RhoJ is associated with gastric cancer progression and metastasis. *Journal of Cancer 2016* (IF 3.609), 7(11):1550-1556

23. **Chon HJ***, Kim HR*, Shin E, **Kim C**, Heo SJ, Lee C, Park JK, Noh SH, Chung HC, Rha SY. The Clinicopathological Features and Prognostic Impact of ALK-positivity in Resected Gastric Cancer Patients. *Annals of Surgical Oncology* 2015 (IF 3.943), 22(12):3938-45
24. Park JS, Jeung HC, Rha SY, Ahn JB, Kang BD, **Chon HJ**, Hong MH, Lim ST, Yang WI, Nam CM, Chung HC. M. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. *Cancer Chemother Pharmacol* 2014 (IF 2.808)
25. Kim C, **Chon HJ**, Kang B, Kim K, Jeung HC, Chung HC, Noh SH, Rha SY. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. *BMC Cancer* 2013 (IF 3.319), 13(1):394.
26. **Chon HJ**, SY Rha, Park HS, Shin SJ, Kim HS, Roh JK, Noh SH, Chung HC, Jeung HCl. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. *Cancer Chemotherapy and Pharmacology* (IF 2.769) October 2011, Volume 68, Issue 4, pp 991-999,
27. Hong MH, Koo HM, Choi J, Ahn JR, **Chon HJ**, Kim C, Lee ST. A case of nephrogenic systemic fibrosis after gadolinium-based contrast agent injection. *Korean Journal of Medicine* 2010, 78(1):127-131.
28. **Chon HJ**, Rha SY, Im CK, Kim C, Hong MH, Kim HR, Ahn JR, Noh SH, Chung HC, Jeung HC. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. *Cancer Research and Treatment* 2009 (IF 2.975), 41(4):196-204.
29. Kim C, Shin E, Hong S, **Chon HJ**, Kim HR, Ahn JR, Hong MH, Yang WI, Roh JK, Rha SY. Clinical value of ezrin expression in primary osteosarcoma. *Cancer Research and Treatment* 2009 (IF 2.975), 41(3):138-144.
30. Ahn JR, Hong M, Kim C, Hong MH, **Chon HJ**, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh SH, Rha SY. Prognosis of pN3 stage gastric cancer. *Cancer Research and Treatment* 2009 (IF 2.975), 41(2):73-79.
31. Hong MH, Kim HS, Kim C, Ahn JR, **Chon HJ**, Shin SJ, Ahn JB, Chung HC, Rha SY. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. *Cancer Research and Treatment* 2009 (IF 2.975), 41(2):67-72.

